RxDoctor Payments Data

Laurie Senol, MD

Internal Medicine · Saint Louis, MONPI 1477521979

Payments from drug & device makers

$2,691in general payments, 2019–2025

Across 97 payments — averaging $27.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$806
  • Amgen$561
  • Lilly USA, LLC$333
  • AbbVie$254
  • Ironshore Pharmaceuticals Inc.$128
  • Biohaven Pharmaceuticals, Inc.$104
  • plus $506 from 18 others

What the payments were for

  • Food & beverage$2,66199%
  • Education$311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,691 in reported general payments places this provider in the 80th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$59,483
Medicare patients
159
Services billed
802

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide66$81,372
EliquisApixaban54$57,074
Repatha SureclickEvolocumab23$21,560
JanuviaSitagliptin Phosphate18$18,718
TrintellixVortioxetine Hydrobromide12$5,914
ArexvyRsvpref3 Antigen/As01e/Pf22$5,821
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$3,720
AbrysvoRsv Vacc, Pref A And Pref B/Pf12$3,694
Rosuvastatin Calcium249$3,506
OxycontinOxycodone Hcl13$3,343
Pantoprazole Sodium122$2,687
Gabapentin140$2,501
SynthroidLevothyroxine Sodium16$2,159
Albuterol Sulfate HfaAlbuterol Sulfate49$1,842
Levothyroxine Sodium164$1,804

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$806$81,37266 claims
PfizerEliquis, Abrysvo$49$60,76866 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$18$5,91412 claims
AbbVieSynthroid$254$2,15916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →